Table 1.
Cohorts characteristics.
| N (%) or median (IQR) | HIV group | Control group | ||
| N | 111 | 63 | ||
| Age, y | 81 | (78–84) | 83.4 | (79.7–88.8) |
| Male | 80 | (72.1) | 20 | (31.7) |
| French-native | 88 | (79.3) | — | |
| Duration of HIV infection, y | 18.2 | (11.8–22.5) | — | |
| Hepatitis HCV/HBV coinfection | 7 | (6.3) | — | |
| CDC stage C | 29 | (26.1) | — | |
| Tobacco active smokers | 4 | (3.6) | — | |
| Body mass index, kg/m2 | 23.4 | (21.6–25.8) | — | |
| On ART | 110 | (99.1) | — | |
| HIV RNA <50 copies/mL | 104 | (94.6) | — | |
| Duration of HIV control, mo | 100 | (37–142) | — | |
| Nadir CD4, cells/mm3 | 174 | (79.2–260) | — | |
| Current CD4, cells/mm3 | 510 | (353–680) | 585 | (401–777) |
| CD4:CD8 ratio | 0.64 | (0.4–1.1) | 2.3 | (1.6–3.3) |
| IgG CMV-positive | 74 | (66.7) | 50.8 | (69.6) |
| No comorbidity | 39 | (35.1) | 7 | (11.1) |
| 1 Comorbidity | 72 | (64.9) | 23 | (36.5) |
| ≥2 Comorbidities | - | 33 | (52.4) | |
| Diabetes mellitus | 14 | (12.6) | 6 | (9.5) |
| Hypertension | 23 | (20.7) | 23 | (36.5) |
| Cardiovascular diseases | 7 | (6.3) | 8 | (12.7) |
| Stroke | 4 | (3.6) | 7 | (11.1) |
| Dyslipidemia | 1 | (0.9) | — | |
| Kidney disease | 1 | (0.9) | 45 | (71.4) |
| Osteoporosis | 1 | (0.9) | — | |
| Neoplasia | 21 | (18.9) | 9 | (14.3) |